Search results for " progression"

showing 10 items of 1092 documents

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Association of CYP2R1 rs10766197 with MS risk and disease progression

2017

Background MS is a neurodegenerative autoimmune disease resulting from a complex interaction of genetic and environmental factors. Among these, vitamin D and genetic variants associated with vitamin D-metabolism gain great attention. The aim of our study was to assess five SNPs in NADSYN1 and CYP2R1 genes in relation to serum 25-OH-vitamin D3 levels in MS patients and controls. Methods 25-OH-vitamin D3 levels and genotyping of CYP2R1- and NADSYN1-SNPs were investigated both in MS patients and in healthy controls. Results The analysis revealed lower 25-OH-vitamin D3 concentrations in MS patients than in controls and an association of rs10766197 CYP2R1 SNP with MS risk. After stratifying MS p…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyPathologyMultiple SclerosisGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideSeverity of Illness IndexpolymorphismDisability Evaluation03 medical and health sciencesCellular and Molecular NeuroscienceSex Factors0302 clinical medicineInternal medicinegendermedicineVitamin D and neurologyHumansSNPGenetic Predisposition to DiseaseNADSYN1AlleleCytochrome P450 Family 2GenotypingRetrospective Studiesbusiness.industryMultiple sclerosisCase-control studyvitamin dMiddle Agedmedicine.diseaseMinor allele frequency030104 developmental biologyCase-Control Studiesmultiple sclerosiDisease ProgressionCYP2R1Cholestanetriol 26-MonooxygenaseFemaleCarbon-Nitrogen Ligases with Glutamine as Amide-N-Donorgeneticbusiness030217 neurology & neurosurgeryJournal of Neuroscience Research
researchProduct

Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B

2017

To evaluate the natural course of disease progression in patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB), identify potential end points for future therapy trials, and characterize biomarkers related to the disease.A prospective, multicenter study was conducted. Baseline, 6-month, and 12-month assessments included neurodevelopmental status (Bayley Scales of Infant Development, Third edition), adaptive status (Vineland Adaptive Behavior Scales, Second Edition), volumetric brain magnetic resonance imaging, cerebrospinal fluid heparan sulfate, and urine glycosaminoglycan (GAG) measurements.Nineteen patients aged 1.6-31.7 years were enrolled. Over 12 months, cognition,…

AdultMale0301 basic medicinePediatricsmedicine.medical_specialtyAdolescentDiseaseBayley Scales of Infant DevelopmentMucopolysaccharidosis IIIYoung Adult03 medical and health sciences0302 clinical medicineMucopolysaccharidosis IIImedicineHumansLongitudinal StudiesProspective StudiesYoung adultChildProspective cohort studyCerebrospinal FluidGlycosaminoglycansSanfilippo syndromemedicine.diagnostic_testbusiness.industryBrainInfantMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingVineland Adaptive Behavior Scale030104 developmental biologyNeurodevelopmental DisordersChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionFemaleHeparitin SulfatebusinessBiomarkers030217 neurology & neurosurgeryThe Journal of Pediatrics
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct

Identification of Differentially Expressed Genes in Papillary Thyroid Carcinomas With and Without Rearrangements of the Tyrosine Kinase Receptors RET…

2005

Background The transforming capacities of RET and/or NTRK1 chimeric oncogenes as well as the molecular background of non-rearranged papillary thyroid carcinomas (PTCs) remain to be elucidated. To assess altered gene expression, we examined PTCs with and without tyrosine kinase receptor rearrangements by mRNA differential display (DD). Materials and methods Six of 13 PTCs examined harbored RET chimeras (3× RET/PTC1, 1× RET/PTC3) and/or NTRK1 chimeras (2× trk, 1× TRK-T3, 2 unknown TRK hybrids). The method of DD analysis was refined by a novel fragment-recovery technique using a high-performance fluorescence scanner. Results Of 500 up- or down-regulated mRNA transcripts, 19 selected fragments …

AdultMaleAdolescentendocrine system diseasesDown-RegulationBiologyReceptor tyrosine kinaseGene expressionHumansThyroid NeoplasmsReceptor trkAGeneAgedCell ProliferationGene RearrangementRegulation of gene expressionGene Expression ProfilingProto-Oncogene Proteins c-retGene rearrangementMiddle AgedCarcinoma PapillaryUp-RegulationGene Expression Regulation NeoplasticGene expression profilingTumor progressionTrk receptorDisease ProgressionCancer researchbiology.proteinFemaleSurgeryJournal of Surgical Research
researchProduct

Associations of reading posture, gaze angle and reading distance with myopia and myopic progression

2016

Purpose To study the associations of habitual reading posture, gaze angle in reading and reading distance with myopia and changes in myopia among myopic children. Methods A total of 240 myopic schoolchildren (mean age 10.9 years), with no previous spectacles, were recruited during 1983–1984 to a randomized 3-year clinical trial of bifocal treatment of myopia. Three annual examinations with subjective cycloplegic refraction were conducted for 237–238 subjects. A further examination was conducted at the mean age of 23.2 years for 178 subjects. Habitual reading posture was elicited by questionnaire at study outset. Reading distance was measured with a Clement Clark accommodometer and gaze angl…

AdultMaleAdolescentgenetic structuresmedia_common.quotation_subjectPosturegaze directionReading distanceSpherical equivalentFixation OcularRefraction OcularSittingYoung Adult03 medical and health sciencesSchool nurse0302 clinical medicinereading distanceSurveys and QuestionnairesReading (process)MyopiaHumansYoung adultChildmedia_commonmyopic progressionreading postureDistance PerceptionAccommodation OcularSitting postureta3142General MedicineGazeeye diseasesta3125OphthalmologyEyeglassesReadingDisease ProgressionVisual Perception030221 ophthalmology & optometryOptometryFemalesense organsPsychology030217 neurology & neurosurgeryheightFollow-Up StudiesActa Ophthalmologica
researchProduct

Pure Progressive Amnesia and the APPV717G Mutation

2009

We report an isolated, slowly progressive, pure amnestic phenotype in a 59-year-old member of a family affected by autosomal dominant familial Alzheimer disease. Early-onset Alzheimer disease in this family was associated with a V717G mutation in the amyloid precursor protein gene (APP). Subjective impairment of episodic memory began in our subject at the age of 44 years and subsequent, longitudinal neuropsychologic assessment confirmed progressive, severe, global impairment of memory functions over a period of 14 years with preservation of other cognitive domains. The mean annual hippocampal atrophy rate, determined by volumetric magnetic resonance imaging was intermediate between values p…

AdultMaleAgingPathologymedicine.medical_specialtyGlycineAmnesiaHippocampusAmyloid beta-Protein PrecursorAtrophyAlzheimer DiseasemedicineHumansDementiaMemory disorderEpisodic memoryAgedSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitive disorderValineMiddle Agedmedicine.diseaseAPPV717G mutation.PedigreePsychiatry and Mental healthClinical PsychologyPhenotypeMutationDisease ProgressionPure progressive amnesiaFemaleAmnesiaAtrophyGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasePsychologyGerontologyFrontotemporal dementia
researchProduct

Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation

2009

Recently, fused in sarcoma/translated in liposarcoma (FUS/TLS) gene, located on chromosome 16p11.2, has been identified as a disease gene in familial amyotrophic lateral sclerosis (FALS). We have analyzed FUS/TLS in a cohort of 52 index cases from seven Italian regions with non-SOD1 and non-TARDBP FALS. We identified a heterozygous c.G1542C missense mutation in a family of northern Italian origin, and a heterozygous c.C1574T missense mutation in a family of Sicilian origin. Both variants are located in exon 15 encoding the RNA-recognition motif, and result in a substitution of an arginine with a serine in position 514 (p.R514S) and substitution of a proline with a leucine at position 525 (p…

AdultMaleAgingamyotrophic lateral sclerosisAdolescentDNA Mutational AnalysisMutation MissenseBiologyArticleCohort StudiesExonYoung AdultDegenerative diseasemedicineMissense mutationHumansFamilygeneticsAmyotrophic lateral sclerosisAge of OnsetGeneamyotrophic lateral sclerosis; geneticsAgedGeneticsGeneral NeuroscienceMiddle Agedmedicine.diseasePhenotypePedigreePhenotypeSLA - FUS mutation - geneticsItalyMutationDisease ProgressionRNA-Binding Protein FUSFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyAge of onsetMissenseAmyotrophic lateral sclerosis; Family pedigrees; FUS gene; Genetics;Developmental BiologyRNA-Binding Protein FUS
researchProduct